Project Grant HT94252410766
Award Date
9/30/24
Completion Date
9/29/26
Dollars Obligated
$490K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
The federal Project Grant award of $1,348,274.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research by Greenstone Biosciences, Inc. to elucidate the mechanistic pathways of LMNA cardiomyopathy and identify novel therapeutic compounds. The funding period runs from May 15, 2024 to May 14, 2028. Greenstone Biosciences, a biotechnology company in Palo Alto, California, is leveraging advanced drug discovery and development...
This $420,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Myogene Bio LLC, a woman-owned small biotechnology company, to evaluate the efficacy of CRISPR gene editing technology in treating Duchenne muscular dystrophy (DMD). The research aims to correlate CRISPR efficacy with functional outcomes in preclinical DMD models, building on the company's previous federal grant awards focused...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
<p>The Defense Health Agency awarded Wake Forest University Health Sciences a $542,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund high-throughput screening to identify lipid nanoparticles effective for systemic delivery to tissues affected by Duchenne muscular dystrophy. The research is scheduled to be completed by September 29, 2025.</p>
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports advanced biomedical research focused on transforming healthcare for military service members and the broader public. The $345,664 award, effective December 1, 2024 through November 30, 2026, will fund research by Royal Holloway and Bedford New College in the United Kingdom to enhance immune protection for an...
The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
This is a $538,218 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by the University of Texas Health Science Center at Houston (UTHealth) to study the role of ERR-alpha in skeletal muscle regeneration and functional recovery for Duchenne muscular dystrophy. The project aims to advance scientific understanding and develop potential treatments for this debilitating...